Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review

被引:5
作者
Gholami, Saeed Sheikh [1 ]
Azar, Farbod Ebadi Fard [2 ]
Rezapour, Aziz [2 ]
Tajdini, Masih [3 ]
机构
[1] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Dept Hlth Econ, Tehran, Iran
[2] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran
[3] Univ Tehran Med Sci, Tehran Heart Ctr, Tehran, Iran
关键词
Cost-effectiveness; Coronary artery disease; Coronary artery bypass graft; Percutaneous coronary intervention; Medical therapy; Economic evaluation; 5-YEAR FOLLOW-UP; MASS-II; HEART-DISEASE; SURGERY; ANGIOPLASTY; UNCERTAINTY; TRIAL;
D O I
10.1007/s10741-019-09811-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
引用
收藏
页码:967 / 975
页数:9
相关论文
共 29 条
[1]  
Allender S, 2014, EUROPEAN CARDIOVASCU
[2]  
Almasiankia A, 2015, SEMJ, V16, P6
[3]   Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region [J].
Augustovski, Federico ;
Iglesias, Cynthia ;
Manca, Andrea ;
Drummond, Michael ;
Rubinstein, Adolfo ;
Garcia Marti, Sebastian .
PHARMACOECONOMICS, 2009, 27 (11) :919-929
[4]  
Baltussen RMPM, 2002, INT J TECHNOL ASSESS, V18, P112
[5]   Optimal medical therapy with or without PCI for stable coronary disease [J].
Boden, William E. ;
O'Rourke, Robert A. ;
Teo, Koon K. ;
Hartigan, Pamela M. ;
Maron, David J. ;
Kostuk, William J. ;
Knudtson, Merril ;
Dada, Marcin ;
Casperson, Paul ;
Harris, Crystal L. ;
Chaitman, Bernard R. ;
Shaw, Leslee ;
Gosselin, Gilbert ;
Nawaz, Shah ;
Title, Lawrence M. ;
Gau, Gerald ;
Blaustein, Alvin S. ;
Booth, David C. ;
Bates, Eric R. ;
Spertus, John A. ;
Berman, Daniel S. ;
Mancini, G. B. John ;
Weintraub, William S. ;
Boden, W. ;
O'Rourke, R. ;
Teo, K. ;
Hartigan, P. ;
Weintraub, W. ;
Maron, D. ;
Mancini, J. ;
Weintraub, W. ;
Boden, W. ;
O'Rourke, R. ;
Teo, K. ;
Hartigan, P. ;
Knudtson, M. ;
Maron, D. ;
Bates, E. ;
Blaustein, A. ;
Booth, D. ;
Carere, R. ;
Ellis, S. ;
Gosselin, G. ;
Gau, G. ;
Jacobs, A. ;
King, S., III ;
Kostuk, W. ;
Harris, C. ;
Spertus, J. ;
Peduzzi, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) :1503-1516
[6]   Treatment for Stable Coronary Artery Disease: A Network Meta-Analysis of Cost-Effectiveness Studies [J].
Caruba, Thibaut ;
Katsahian, Sandrine ;
Schramm, Catherine ;
Nelson, Anais Charles ;
Durieux, Pierre ;
Begue, Dominique ;
Juilliere, Yves ;
Dubourg, Olivier ;
Danchin, Nicolas ;
Sabatier, Brigitte .
PLOS ONE, 2014, 9 (06)
[7]   CORONARY-ARTERY SURGERY STUDY (CASS) - COMPARABILITY OF 10 YEAR SURVIVAL IN RANDOMIZED AND RANDOMIZABLE PATIENTS [J].
CHAITMAN, BR ;
RYAN, TJ ;
KRONMAL, RA ;
FOSTER, ED ;
FROMMER, PL ;
KILLIP, T .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 16 (05) :1071-1078
[8]   Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease -: Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME) [J].
Claude, J ;
Schindler, C ;
Kuster, GM ;
Schwenkglenks, M ;
Szucs, T ;
Buser, P ;
Osswald, S ;
Kaiser, C ;
Grädel, C ;
Estlinbaum, W ;
Rickenbacher, P ;
Pfisterer, M .
EUROPEAN HEART JOURNAL, 2004, 25 (24) :2195-2203
[9]  
Drummond M, 2015, METHODS EC EVALUATIO
[10]   Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010 [J].
Fidan, D. ;
Unal, B. ;
Critchley, J. ;
Capewell, S. .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2007, 100 (05) :277-289